The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of pembrolizumab plus lenvatinib and belzutifan in patients with metastatic esophageal squamous cell carcinoma.
 
Carlos Rojas
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Knight Therapeutics/Biotoscana; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb/Celgene; Knight Therapeutics/Biotoscana; Merck; Pfizer; Roche
Expert Testimony - AstraZeneca; Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Baek-Yeol Ryoo
No Relationships to Disclose
 
Sun Young Rha
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eisai; Eutilex; indivumed; LG Chem; MSD Oncology; Ono Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; BMS/Ono; Daiichi Sankyo/UCB Japan; Eisai; Lilly; MSD Oncology
Research Funding - Amgen (Inst); ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb; Daichii Sankyo; Eisai; Indivumed; Lilly; MSD Oncology; Roche/Genentech; Sillajen; Zymeworks
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); Kinnate Biopharma; Merck (Inst); Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck
 
Ayala Hubert
No Relationships to Disclose
 
Claudio Painemal
No Relationships to Disclose
 
Raymond Couric Wadlow
Honoraria - AstraZeneca; Oncocyte; Pfizer; Seagen; Taiho Pharmaceutical
Consulting or Advisory Role - Exact Sciences; Johnson & Johnson (I)
Travel, Accommodations, Expenses - Exact Sciences
 
Jun Gong
Honoraria - Amgen; Astellas Pharma; AVEO; Basilea Pharmaceutical; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono; Exelixis; HalioDx; Incyte; Janssen Biotech; Natera; Pfizer/Myovant; QED Therapeutics
Consulting or Advisory Role - Amgen; Astellas Pharma; AVEO; Basilea; Bayer; Clinical Congress Consultants; Eisai; Elsevier; EMD Serono/Merck; Exelixis; HalioDx; Incyte; Janssen Biotech; MJH Life Sciences; Natera; OncLive/MJH Life Sciences; Pfizer/Myovant; QED Therapeutics; Seagen
Patents, Royalties, Other Intellectual Property - PCT/US2021/043961 provisional patent on glutamine and cancer; U.S. Provisional Application Serial No. 63/315,895 on methylated ctDNA markers
 
Li Fan
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
 
Fan Jin
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Girish S. Naik
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - pending patent applications for use of DKK1 inhibitors in cancer.
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Teresa Macarulla
Consulting or Advisory Role - Ability Pharma; Advance Medical; Amgen; Aptitude Health; AstraZeneca; Basilea; Baxter; BioLineRX; Celgene; Eisai; Ellipses Pharma; Esteve; Incyte; Ipsen; Janssen; Lilly; Medscape; MFAR, Marketing Farmacéutico & Investigación Clínica; MSD; Novocure; Paraxel; Prime Oncology; QED Therapeutics; Roche; Sanofi/Aventis; SERVIER; Zymeworks
Research Funding - Abbvie (Inst); Ability Pharma (Inst); Agios (Inst); Amc Medical Research (Inst); Amgen (Inst); Armo Biosciences (Inst); ASLAN Pharmaceuticals (Inst); ASTRAZENECA (Inst); Basilea Pharmaceutical (Inst); Bayer (Inst); Beigene (Inst); BiolineRx (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (BMS) (Inst); Cantargia AB (Inst); Celgene (Inst); Eisai (Inst); ERYTECH Pharma (Inst); Fibrogen (Inst); Genentech (Inst); Halozyme (Inst); Immunomedics (Inst); Incyte (Inst); Ipsen (Inst); Keralty Group (Inst); Lilly (Inst); Loxo (Inst); Medimmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Millennium (Inst); Nelum Corp. (Inst); Novartis (Inst); Novocure (Inst); OncoMed (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst); Roche (Inst); VCN Biosciences (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - Celgene; H3 Biomedicine; Incyte; Merck; Prime Oncology; Sanofi; SERVIER